Quintrio
Home

ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES

Myomo Inc.

MYO

Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA). Geographically, it derives maximum revenue from the United States, followed by Germany, and other international.

Last trade $0.9702
Day change -$0.0498 (-4.88%)
Day range $0.965 – $1.06
Volume 309,737
Market cap $41M

Open XASE

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$40.9M
Price / earnings
—
Price / book
14.87×
Price / sales
0.9×
EV / sales
0.95×
EV / EBITDA
-5.05×

Profitability

Earnings per share
-$0.38
Return on assets
-44.6%
Return on equity
-548.13%
Dividend yield
0%

Liquidity and leverage

Debt / equity
4.89×
Current ratio
1.92×
Quick ratio
1.66×
Cash ratio
0.9×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$7.42M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for MYO, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$12.33M$11.7M$10.11M$11.35M$10.09M$9.65M$9.83M$12.07M
Cost of revenue$3.54M$3.26M$3.21M$3.57M$3.65M$3.6M$3.22M$3.45M
Gross profit$8.79M$8.44M$6.9M$7.78M$6.44M$6.05M$6.61M$8.62M
Selling, general and administrative$8.7M$8.98M$8.44M$8.93M$8.43M$8.64M$8.34M$7.3M
Research and development$1.81M$1.72M$1.62M$1.62M$1.53M$2M$1.79M$1.56M
Total operating expenses$10.51M$10.7M$10.06M$10.56M$9.96M$10.64M$10.13M$8.86M
Operating income-$1.72M-$2.25M-$3.16M-$2.77M-$3.52M-$4.59M-$3.52M-$245.31K
Interest expense-$559.77K-$535.74K-$504.7K$0-$9.74K$106.55K$191.99K$0
Income before taxes-$4.13M-$3.99M-$2.82M-$3.73M-$3.53M-$4.48M-$3.33M-$175.28K
Income taxes$103.87K$31.4K$186.72K$83.88K$135.66K$148.2K$136.8K$84.8K
Net income-$4.23M-$4.02M-$3.01M-$3.81M-$3.66M-$4.63M-$3.47M-$260.08K
Net income attributable to common shareholders-$4.23M-$4.02M-$3.01M-$3.81M-$3.66M-$4.63M-$3.47M-$260.08K
EBITDA-$1.32M-$1.87M-$2.87M-$2.51M-$3.27M-$4.4M-$3.36M-$153.75K
Basic earnings per share-$0.10-$0.09-$0.07-$0.09-$0.09-$0.11-$0.08-$0.01
Diluted earnings per share-$0.10-$0.09-$0.07-$0.09-$0.09-$0.11-$0.08-$0.01

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Myomo (MYO) Upgraded to Buy: What Does It Mean for the Stock?

Myomo, Inc. (MYO) has been upgraded to a Zacks Rank #2 (Buy) rating, primarily driven by upward trends in earnings estimates. The company's consensus estimate has increased 4.5% over the past three months. The upgrade positions Myomo in the top 20% of Zacks-covered stocks, suggesting potential near-term stock price appreciation based on improving earnings outlook.

Zacks Investment Research

Myomo, Inc. (MYO) Reports Q3 Loss, Beats Revenue Estimates

Myomo (MYO) reported a quarterly loss of $0.07 per share, beating consensus estimates of $0.08 loss, with revenues of $12.33 million exceeding expectations by 9.12%. The stock has gained 33% year-to-date, outperforming the S&P 500's 7.8% gain. However, the company maintains a Zacks Rank #3 (Hold) rating due to mixed estimate revisions, and its industry (Medical - Products) ranks in the bottom 41% of sectors.

Zacks Investment Research

Bio-Rad Laboratories (BIO) Q3 Earnings Top Estimates

Bio-Rad Laboratories reported Q3 2026 earnings of $2.65 per share, beating consensus estimates of $2.61, but revenues of $656.4 million missed expectations by 0.83%. The stock has outperformed the S&P 500 by 13.1% year-to-date. Despite the earnings beat, Bio-Rad received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market. The Medical-Products industry ranks in the bottom 37% of Zacks industries.

Zacks Investment Research

Myomo, Inc. (MYO) Reports Q4 Loss, Tops Revenue Estimates

Myomo, Inc. (MYO) delivered earnings and revenue surprises of -40% and 1.19%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Benzinga

Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Shares of Zscaler, Inc. (NASDAQ: ZS) shares fell sharply during Friday’s session following second-quarter results. Zscaler posted better-than-expected earnings and sales results for its second quarter on Thursday. The company said it expects fiscal year 2024 non-GAAP income from operations between $395 million and $400 million and net income per share between $2.73 and $2.77. Zscaler shares fell 10.1% to $217.43 on Friday. Here are some other stocks moving in today's mid-day session. Gainers BioVie Inc. (NASDAQ: BIVI) shares climbed 96.1% to $2.4319. BioVie's Ne3107 demonstrated potential improvements in motor and non-motor symptoms for Parkinson's disease patients and may be realigning physiological processes for Alzheimer's patients. Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) gained 68.4% to $3.4350. Adial Pharmaceuticals was awarded a new patent covering AD04 for the potential treatment of opioid use disorder. Cardiff Oncology, Inc. (NASDAQ: CRDF) shares rose 41.5% to $2.50 after the company reported better-than-expected fourth-quarter financial results, provided a clinical update on the Phase 2 randomized second-line ONSEMBLE trial in patients with RAS-mutated mCRC and announced the first patient was dosed in the randomized first-line RAS-mutated mCRC trial. Minim, Inc. (NASDAQ: MINM) shares rose 41.4% to $6.09. On Feb. 20, Minim entered into an employment agreement with David Lazar to engage him as CEO, CFO, following resignation of Jeremy Hitchcock. The RealReal, Inc. (NASDAQ: REAL) gained 39.1% to $2.4613 following upbeat quarterly results. Nxu, Inc. (NASDAQ: NXU) shares gained 36.4% to $1.09 after the company announced it successfully charged a Tesla Cybertruck on Feb. 26. Jaguar Health, Inc. (NASDAQ: JAGX) climbed 35.3% to $0.0798. Dell Technologies Inc. (NYSE: DELL) rose 26.3% to $119.52 as the company reported better-than-expected fourth-quarter financial results and increased its annual cash dividend by 20%. Sweetgreen, Inc. (NYSE: SG) gained 26% to $16.05 after the company reported better-than-expected fourth-quarter financial results. MMTec, Inc. (NASDAQ: MTC) climbed 25% to $1.61. Everbridge, Inc. (NASDAQ: EVBG) rose 24.5% to $35.19 after it amended and restated the previously announced merger agreement with Thoma Bravo. NetApp, Inc. (NASDAQ: NTAP) shares gained 24.4% to $110.85 after the company reported better-than-expected third-quarter financial results ...

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jan 31, 20201-for-30reverse split